Life Sciences Tools & Services
WST delivered a strong Q1 FY2026 with revenue surging 21.0% YoY to $844.9M and operating income jumping 65.5% to $177.1M, driven by significant margin expansion, though operating cash flow declined 30.5% amid aggressive share buybacks.
Key risk: Operating Cash Flow Decline Despite Strong Earnings
Operating cash flow fell 30.5% YoY to $89.9M despite net income of $138.8M, suggesting potential working capital headwinds or timing differences in cash collections. If this divergence between earnings and cash generation persists, it could constrain WST's ability to fund operations and capital returns simultaneously.
Other Health Care Supplies companies